Cytokinetics Inc (NAS:CYTK)
$ 48.405 -0.575 (-1.17%) Market Cap: 5.08 Bil Enterprise Value: 5.30 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc Licensing Collaboration And Royalty Monetization Deals With RTW Investments Focused To CK-274 Corporate Call Transcript

Jul 14, 2020 / 12:30PM GMT
Release Date Price: $27.88 (+16.07%)
Operator

Good morning and welcome, ladies and gentlemen, to Cytokinetics' Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)

I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser
Cytokinetics, Incorporated - SVP of Corporate Communications & IR

Good morning, everyone, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will lead us off today with an overview of today's announcement. Then Libby Schnieders, Senior Vice President of Business Development, will speak to the multiple components underlying the deal before Ching Jaw, our SVP and Chief Financial Officer, will summarize the financial terms of the deals and how they inform our financial outlook. Next, Fady Malik, our Executive Vice President of R&D, will discuss the impact of these transactions on the development program for CK-274 before Robert provides final comments and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot